Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443820 (Oditrasertib) in Adult Participants With Amyotrophic Lateral Sclerosis
NCT05237284Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of oditrasertib in amyotrophic lateral sclerosis (ALS), sponsored by Sanofi. Started Apr 2022; status: terminated.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05237284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237284.